eGFR | MDRD | <15 | 15–29 | 30–59 | 60–89 | >90 | Totals |
CKD-EPI | CKD stage | 5 | 4 | 3 | 2 | 1/0 | |
<15 | 5 | 30 709 | 4962 | 0 | 0 | 0 | 35 671 |
15–29 | 4 | 374 | 169 647 | 34 454 | 0 | 0 | 204 475 |
30–59 | 3 | 0 | 2808 | 2 053 741 | 91 096 | 0 | 2 147 645 |
60–89 | 2 | 0 | 0 | 285 367 | 6 700 219 | 339 013 | 7 324 599 |
>90 | 1/0 | 0 | 0 | 0 | 2 253 536 | 4 481 137 | 6 734 673 |
Totals | 31 083 | 177 417 | 2 373 562 | 9 044 851 | 4 820 150 | 16 447 063 |
The table design and coding is based on that of table 1. Columns indicate the MDRD results and show the redistribution of patients in these CKD groups on the basis of eGFR when assessed using the CKD-EPI formula, shown in rows. Numbers in bold indicate those who do not change CKD category with a change from the MDRD to the CKD-EPI formula. Below these, underlined figures indicate the numbers who move into a better CKD category and above and italicised figures indicate the numbers of patients who move into a worse CKD stage. Both CKD stages 1 and 2 require a structural or other abnormality in addition to the eGFR criteria.
CKD, chronic kidney disease; CKD-EPI, chronic kidney disease-epidemiology collaboration; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.